Back to News
Market Impact: 0.15
InflaRx N.V. Announces Publication of Phase 1 Data for Izicopan
Source: Nasdaq
Healthcare & BiotechTechnology & Innovation
InflaRx announced peer-reviewed publication of first-in-human Phase 1 clinical data for izicopan, formerly INF904, an orally administered small-molecule C5aR1 inhibitor. The supplied article excerpt ends before reporting the study’s results, so it provides no efficacy, safety, or other clinical figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
IFRX0.55
More News
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Asian Markets Tally Losses From Worsening Global Rout
- AI’s Grip on Financial Markets Was Never Clearer on the Way Down
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- OpenAI valued at $1.25 trillion, as rival Anthropic nears its IPO
- AI Party isn't Ending Because Of The Blue Wave Says Ives